Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 4/20 | 0.79 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.69 |
| ▸ | NPY1R | P25929 | 1/20 | 0.69 |
| ▸ | NPY2R | P49146 | 1/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.68 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.68 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | CNR1 | P21554 | 1/20 | 0.67 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.67 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1269430 | 0.99 | ADRB2 (0.77) | ADRB2ADRB1TDP1PMP22NPY1R | |
| SCHEMBL11021642 | 0.92 | ADRB2 (0.72) | ADRB2ADRB1TDP1PMP22NPY1R | |
| Hydrochloric Acid SCHEMBL28539285 | 0.91 | ADRB2 (0.70) | ADRB2ADRB1TDP1PMP22NPY1R | |
| Metoprolol SCHEMBL2406939 | 0.89 | ADRB1 (0.84) | ADRB2ADRB1TDP1PMP22NPY1R | |
| Metoprolol SCHEMBL40917 | 0.89 | ADRB1 (0.84) | ADRB2ADRB1TDP1PMP22NPY1R | |
| Metoprolol SCHEMBL23668766 | 0.89 | ADRB1 (0.84) | ADRB2ADRB1TDP1PMP22NPY1R | |
| Metoprolol SCHEMBL14744146 | 0.89 | ADRB1 (0.84) | ADRB2ADRB1TDP1PMP22NPY1R | |
| Metoprolol SCHEMBL40916 | 0.89 | ADRB1 (0.84) | ADRB2ADRB1TDP1PMP22NPY1R | |
| (S)-Metoprolol SCHEMBL379724 | 0.89 | ADRB1 (0.84) | ADRB2ADRB1TDP1PMP22NPY1R | |
| SCHEMBL20552238 | 0.88 | ADRB2 (0.77) | ADRB2ADRB1TDP1PMP22NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116036305-B | Nanometer medicine and its prepn and application | 广州国家实验室 | 2023-09-15 | — | — | CN | claimed |
| CN-116036305-A | Nanometer medicine and its prepn and application | 广州国家实验室 | 2023-05-02 | — | — | CN | claimed |
| US-9078882-B2 | Compositions and methods for preventing cardiac arrhythmia | CORMATRIX CARDIOIOVASCULAR, INC. (US) | 2015-07-14 | — | — | US | claimed |
| US-20150164960-A1 | Compositions and Methods for Preventing Cardiac Arrhythmia | ELUTIA MED LLC | 2015-06-18 | — | — | US | claimed |
| EP-0403578-B1 | STABLE PHARMACEUTICAL COMPOSITION | OHMEDA (GB) | 1994-10-12 | — | — | EP | claimed |
| EP-0041491-B1 | NEW PARA-SUBSTITUTED 3-PHENOXY-1-ALKYLAMINO-PROPANOL-2-S HAVING BETA RECEPTOR BLOCKING PROPERTIES | Aktiebolaget Hässle (SE) | 1985-01-30 | — | — | EP | claimed |
| CN-115951003-B | Method for detecting impurity of esmolol hydrochloride injection | 湖南省药品检验检测研究院 | 2024-12-24 | — | — | CN | disclosed |
| EP-3310439-B1 | PHARMACEUTICAL COMPOSITIONS FOR ANESTHESIOLOGICAL APPLICATIONS COMPRISING BENZODIAZEPINE AND KETAMINE | MELT PHARMACEUTICALS INC (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-116036305-B | Nanometer medicine and its prepn and application | 广州国家实验室 | 2023-09-15 | — | — | CN | disclosed |
| CN-116036305-A | Nanometer medicine and its prepn and application | 广州国家实验室 | 2023-05-02 | — | — | CN | disclosed |
| US-11622955-B2 | Sigma-1 receptor agonist systolic blood pressure therapy | ANAVEX LIFE SCIENCES CORP. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20230071766-A1 | SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY | ANAVEX LIFE SCIENCES CORP. (US) | 2023-03-09 | — | — | US | disclosed |
| US-11193925-B2 | Medication adherence monitoring device | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20160367566-A1 | PHARMACEUTICAL COMPOSITIONS FOR ANESTHESIOLOGICAL APPLICATIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2016-12-22 | — | — | US | disclosed |
| EP-0403578-B1 | STABLE PHARMACEUTICAL COMPOSITION | OHMEDA (GB) | 1994-10-12 | — | — | EP | disclosed |
| EP-0403578-A4 | STABLE PHARMACEUTICAL COMPOSITION | — | 1991-07-03 | — | — | EP | disclosed |
| EP-0403578-A1 | STABLE PHARMACEUTICAL COMPOSITION. | DU PONT (US) | 1990-12-27 | — | — | EP | disclosed |
| WO-1989011855-A1 | STABLE PHARMACEUTICAL COMPOSITION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-12-14 | — | — | WO | disclosed |
| US-4857552-A | DEGRADABLE ESMOLOL HYDROCHLORIDE FOR CARDIOVASCULAR DISORDERS; SHORT ACTION, SHELF LIFE | E. I. DU PONT DE NEMOURS AND CO. (US) | 1989-08-15 | — | — | US | disclosed |
| EP-0041491-A1 | New para-substituted 3-phenoxy-1-alkylamino-propanol-2-s having beta receptor blocking properties | Aktiebolaget Hässle (SE) | 1981-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367566-A1 | PHARMACEUTICAL COMPOSITIONS FOR ANESTHESIOLOGICAL APPLICATIONS | GRIN2B, GRIN3A, GABRB1 | ADRB2 34/4885ADRB1 40/4885TDP1 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.